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A deficient mismatch repair system (dMMR) is present in 10–20% of patients with sporadic colorectal cancer (CRC) and is
associated with a favourable prognosis in early stage disease. Data on patients with advanced disease are scarce. Our aim was to
investigate the incidence and outcome of sporadic dMMR in advanced CRC. Data were collected from a phase III study in 820
advanced CRC patients. Expression of mismatch repair proteins was examined by immunohistochemistry. In addition microsatellite
instability analysis was performed and the methylation status of the MLH1 promoter was assessed. We then correlated MMR status
to clinical outcome. Deficient mismatch repair was found in only 18 (3.5%) out of 515 evaluable patients, of which 13 were caused by
hypermethylation of the MLH1 promoter. The median overall survival in proficient MMR (pMMR), dMMR caused by
hypermethylation of the MLH1 promoter and total dMMR was 17.9 months (95% confidence interval 16.2–18.8), 7.4 months
(95% CI 3.7–16.9) and 10.2 months (95% CI 5.9–19.8), respectively. The disease control rate in pMMR and dMMR patients was 83%
(95% CI 79–86%) and 56% (30–80%), respectively. We conclude that dMMR is rare in patients with sporadic advanced CRC. This
supports the hypothesis that dMMR tumours have a reduced metastatic potential, as is observed in dMMR patients with early stage
disease. The low incidence of dMMR does not allow drawing meaningful conclusions about the outcome of treatment in these
patients.
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In recent years the median overall survival (OS) for patients with
advanced colorectal cancer (CRC) has significantly improved,
mainly because of the availability of cytotoxic agents such as
oxaliplatin and irinotecan, and the targeted drug bevacizumab
(Punt, 2004). Despite these improvements cure is only rarely
achieved, and not all patients respond to chemotherapy. Therefore,
there is a need for predictive and prognostic tests that identify
patients who may or may not benefit from systemic treatment.
Deficient mismatch repair (dMMR) is one of the genetic
pathways that is involved in the development of CRC (Aaltonen
et al, 1993; Ionov et al, 1993). Microsatellites are repetitive units in
DNA. In normal circumstances insertions or deletions in these
regions are repaired by the MMR system, which consists of several
cooperating MMR proteins. Dysfunction of this system is causing
dMMR. Known MMR gene products are: MLH1, MSH2, MSH6 and
PMS2. A germ line mutation in one of these corresponding genes,
most often MLH1 or MSH2, is the cause of dMMR in patients with
Lynch syndrome, formerly Hereditary Non Polyposis Colorectal
Cancer (HNPCC), which comprises 0.8–5% of all CRCs (Mecklin,
1987; Rodriguez-Bigas et al, 1997; Cunningham et al, 2001).
Deficient mismatch repair is also observed in 10–20% of patients
with sporadic CRC, usually caused by MLH1 promoter hyper-
methylation (Lothe et al, 1993; Kane et al, 1997; Cunningham et al,
1998; Peltomaki, 2003). Microsatellite analysis is the gold standard
for the detection of dMMR in patients with a suspicion of Lynch
syndrome, as well as in tumours with indecisive results of IHC.
Lindor et al (2002) showed that immunohistochemistry (IHC) in
colorectal tumours for MLH1 and MSH2 provides a rapid, cost-
effective, sensitive (92.3%) and highly specific (100%) method for
screening for DNA MMR defects, which was recently confirmed by
our group (Overbeek et al, 2008).
Colorectal carcinomas with dMMR show several distinct
pathological features, such as a location in the proximal colon, a
poor histological differentiation, high numbers of tumour
infiltrating lymphocytes, and are more often of mucinous type.
Moreover patients with dMMR tumours have a better prognosis
compared to patients with proficient MMR (pMMR) tumours
(Sankila et al, 1996; Gryfe et al, 2000; Samowitz et al, 2001; Ward
et al, 2001; Popat et al, 2005). Several studies investigated if
chemosensitivity is implied in the better prognosis of patients
with a dMMR tumour. In vitro studies have shown dMMR cell lines
to be resistant to 5-fluorouracil (5FU) (Carethers et al, 1999;
Arnold et al, 2003), but not to oxaliplatin (Fink et al, 1996; Sergent
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set al, 2002) or irinotecan (Magrini et al, 2002). In patients receiving
adjuvant chemotherapy for CRC, conflicting results have been
reported on the correlation between dMMR and outcome in
retrospective studies (Elsaleh and Iacopetta, 2001; Ribic et al, 2003;
Carethers et al, 2004; Benatti et al, 2005). Therefore, the ASCO
2006 and European 2007 guidelines do not recommend the
use of dMMR as a prognostic and/or predictive marker in this
setting (Locker et al, 2006; Duffy et al, 2007). Only few data from
small, non-randomised studies are available on the function of
dMMR in patients with advanced CRC (Popat et al, 2005). In most
of these studies sporadic and hereditary CRC were not clearly
differentiated. Histopathological and clinical differences between
tumours with a mutation of a MMR gene and tumours with
hypermethylation of the MLH1 promoter as a cause of dMMR have
been described (Benatti et al, 2005; Jass, 2007), and therefore it
seems reasonable to distinguish between these two types of dMMR
tumours regarding response to therapy and survival (Poynter et al,
2008).
This is the first randomised study with chemotherapy in patients
with advanced CRC which evaluates the incidence of dMMR and
its correlation with clinical outcome.
MATERIALS AND METHODS
Study population
Tumour tissue was obtained from patients enrolled in a
randomised phase III study, the CAIRO study of the Dutch
Colorectal Cancer Group (DCCG), registered with ClinicalTrials.
gov with the number NCT00312000, of which the results on
survival have been published (Koopman et al, 2007). In this study
820 patients were randomised between first-line capecitabine,
second-line irinotecan and third-line capecitabineþoxaliplatin
(sequential treatment arm) vs first-line capecitabineþirinotecan,
and second-line capecitabineþoxaliplatin (combination treatment
arm). The primary endpoint was OS, and secondary endpoints
included response rate, and progression-free survival (PFS).
Assessment of tumour response was scheduled every three cycles
(9 weeks) according to RECIST criteria (Therasse et al, 2000).
Follow-up after completion of treatment was carried out every
3 months until death. For this study formalin-fixed paraffin-
embedded material of the primary tumour and normal tissue was
obtained from 515 patients out of 803 eligible patients of the
CAIRO study. No tissue material was obtained in 288 patients
because a resection of the primary tumour was not performed, or
there was insufficient or non-available material.
Histology and pathology
Histopathologic evaluation was carried out by two independent
observers, and in case of discordant results, the opinion of a third
observer (pathologist: JvK) was final. Histopathological subtype
and grade of differentiation were determined according to WHO
criteria (Jass et al, 1990). Tumours were classified as right-sided
(proximal of the splenic flexure), left-sided (distal of the splenic
flexure) or rectal.
Immunohistochemistry
IHC was performed on formalin-fixed paraffin-embedded tissue.
Of each paraffin-embedded block a 2mm punch for assembling
tissue microarrays (TMA’s) was accomplished as previously
described (Hendriks et al, 2003). Four 4mm slides were assessed
of every TMA and mounted on glass. The TMA slides were
deparaffined and afterwards the tissues were rehydrated using
xylene and ethanol. Water and phosphate-buffered saline (PBS)
were used for washing of the slides. Endogenous peroxidase
activity was blocked with 3% hydrogen peroxide in PBS for 30min
and slides were washed with water, after which heat-induced
epitope retrieval was performed. The slides were stained with
antibodies against MLH1 (clone G168-15; BD Biosciences, San
Jose, CA, USA), MSH2 (clone GB12; Calbiochem, Darmstadt,
Germany), MSH6 (clone 44; BD Biosciences) and PMS2 (clone
A16-4; BD Biosciences). The scoring was performed by two blinded
observers, and if the slide scoring was not unambiguous, the
opinion of a third observer (pathologist: JvK) was final. Staining
pattern of the MMR proteins was evaluated by using the normal
epithelial, stromal and inflammatory cells as internal control.
Protein expression was scored positive if at least one cancer cell
nucleus showed staining, negative if none of the tumour cells
showed staining with positive internal control, and not applicable
if neither tumour nor stromal cells showed protein expression. In
case of absence of MMR protein or not interpretable results of
IHC, the IHC stainings on TMA were repeated on whole tissue
slides for final scoring.
Microsatellite instability analysis
Microsatellite instability (MSI) analysis was performed for
tumours of which the final IHC staining was not interpretable or
with a negative staining for at least one of four mismatch repair
proteins. In addition a random sample of 54 tumours was taken
from the pMMR tumours. DNA was extracted from formalin-fixed
paraffin-embedded tissues of tumour mucosa and corresponding
normal mucosa by a standard procedure. Areas containing 450%
tumour cells were selected by microscopic evaluation on a
reference slide stained with H&E. Slides (50mm thick) were made,
and if necessary tumour cells were prepared using a scalpel. MSI
status was determined by PCR and GeneScan analysis using two
microsatellite markers (BAT 25 and BAT 26). If only one of these
markers showed instability, the analysis was extended with four
additional markers (BAT 40, D2S123, D5S346, D17S250) (Boland
et al, 1998; Samowitz et al, 1999). A tumour was defined dMMR if
at least two of the six markers showed instability, or pMMR if none
of the markers showed any shift in mobility. MSI-low tumours
with only one of the markers showing instability were included in
the pMMR category. For the distinction between dMMR tumours
caused by hypermethylation of the MLH1 promoter and mutation
of one of the mismatch repair genes, dMMR tumours were further
analysed for hypermethylation of the MLH1 promoter (Bettstetter
et al, 2007).
Hypermethylation of MLH1 promoter
The DNA methylation status of the MLH1 promoter region was
determined after bisulphite treatment of the DNA using the EZ
DNA methylation KIT, ZYMO Research (Orange, CA, USA), as
described before (Overbeek et al, 2007).
Statistical analysis
Patients were divided into three groups: pMMR tumours, dMMR
tumours caused by hypermethylation of the MLH1 promoter and
dMMR tumours without hypermethylation of the MLH1 promoter.
Survival analysis was performed for patients with pMMR tumours
vs dMMR tumours caused by hypermethylation of the MLH1
promoter and vs the total group of patients with a dMMR tumour,
respectively. The association between dMMR and patient or
tumour characteristics was investigated with an univariate logistic
regression model. Patients were considered evaluable for response
if they had completed at least three cycles of chemotherapy.
Disease control was defined by stable disease with a duration of
X4 months or partial response or complete response. Differences
in response and disease control rates were analysed by a w
2
(univariate) model. The PFS was calculated for first-line treatment,
from the date of randomization to the first observation of disease
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sprogression or death from any cause reported after first-line
treatment. OS and PFS curves were estimated using the
Kaplan–Meier method and compared using a Cox proportional
hazard model. All tests were two-sided and P-values of less than
0.05 were considered significant. All data received before May 2008
are included in this report with a median follow-up of 43 months.
All analyses were performed using SAS 9.1 and S-plus 6.2 software.
RESULTS
IHC, MMR and hypermethylation of the MLH1 promoter
Figure 1 shows the results on IHC, MMR and hypermethylation of
the MLH1 promoter. Samples of 515 eligible patients were available
for IHC. In 498 tumours no loss for MMR gene products was
observed, 14 tumours showed loss of MLH1 in combination with
PMS2, 2 tumours showed loss of MSH6 of which one in
combination with MSH2, and in one tumour the IHC staining
was not evaluable. All these 17 tumours with loss/not evaluable
IHC result of at least one MMR protein turned out to be dMMR by
MSI analysis. In 54 tumours without loss of MMR gene products
(random sample), dMMR was detected in 1 tumour by MSI
analysis, resulting in a total of 18 dMMR tumours (3.5%).
Hypermethylation of the MLH1 promoter was found in 13 out of
these 18 tumours, all with protein loss of MLH1 by IHC. This
resulted in 515 patients for the analysis: 18 with a dMMR tumour
(3.5%), of which 13 patients with a dMMR tumour caused by
hypermethylation of the MLH1 promoter, and 497 patients with a
pMMR tumour.
Patient characteristics and MMR status
Patient characteristics of the three groups of patients are presented
in Table 1. The median age of the included patients was 63 years
(range 31–81). Significant differences between the group of
patients with dMMR caused by hypermethylation of the MLH1
promoter and the pMMR group were seen for the location
(Po0.0001) and differentiation grade of the primary tumour
(P¼0.025). Patients with a dMMR tumour not caused by MLH1
promoter hypermethylation were younger than patients with a
dMMR tumour caused by MLH1 promoter hypermethylation
(P¼0.0051). The univariate analysis showed an association of
poorly differentiated features with an increased probability of
exhibiting dMMR, patients with a poor/undifferentiated tumour
IHC results of 515 eligible patients with advanced  
CRC 
No loss of MMR gene products (n=498)  loss of MMR gene products (n=16) 
- loss of MLH1 + PMS2 (n=14) 
- loss of MSH2 + MSH6 (n=1) 
- loss of MSH6 (n=1) 
IHC result not evaluable (n=1) 
Total n=16 
  - dMMR n=16 
  - pMMR n=0 
Total n=54 (random sample) 
  - dMMR n=1 
  - pMMR n=53  
Total n=1 
   - dMMR n=1 
   - pMMR n=0 
MSI analysis (n=71) 
Analysis of hypermethylation of MLH1 promoter in dMMR tumours (n=18) 
Total n=1 
- no hypermethylation n=1 
of which IHC result: no 
losses
Total n=16 
- hypermethylation of  MLH1 promoter n=13  
of which IHC results: 
  - loss of MLH1 n=13 
- no hypermethylation MLH1 promoter n=3 
  of which IHC results: 
- loss of MSH2 + MSH6 n=1 
- loss of MSH6 n=1 
- loss of MLH1 n=1  
Total n=1 
- no hypermethylation of MLH1 promoter 
n=1
of which IHC result:not evaluable
Total n=515 
- pMMR tumors n=497 (96.5%) 
- dMMR tumors n=18 (3.5%): 
   - dMMR tumors caused by hypermethylation of MLH1 promoter n=13 (2.5%) 
   - dMMR tumors not caused by hypermethylation of  MLH1 promoter n=5 (1.0%) 
Figure 1 IHC results, MSI analysis and hypermethylation MLH1 promoter.
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shave a 3.9 times increased risk of exhibiting dMMR compared to
well/moderate differentiated tumours (P¼0.025).
OS and PFS in relation to MMR status of the tumour
At the time of this analysis 447 patients have died, of which 15
patients exhibited dMMR. Table 2 presents the median OS and PFS
for the pMMR and dMMR group of patients. The median OS was
17.9 months (95% CI 16.2–18.9), 7.4 months (95% CI 3.7–16.9)
and 10.2 months (95% CI 5.9–19.8) for patients with a pMMR
tumour, a dMMR tumour caused by hypermethylation of the
MLH1 promoter, and the total group of patients with a dMMR
tumour, respectively (Table 2; Figure 2). These differences were
statistically not significant (Table 2). In the sequential treatment
arm, the median OS for these groups of patients was 17.2 months
(95% CI 14.7–18.8), 12.4 months (95% CI 3.2–-4) and 12.7
months ((95% CI 7.4–22.2), respectively, and in the combination
treatment arm 18.3 months (95% CI 16.2–20.6), 6.2 months (95%
CI 3.6–31.3) and 6.2 months (95% CI 3.6–31.3), respectively. All
these differences were statistically not significant (Table 2).
The median PFS for patients with a pMMR tumour, dMMR
tumours caused by hypermethylation of the MLH1 promoter, and
the total group of patients with a dMMR tumour, was 6.9 months
(95% CI 6.3–7.7), 4.3 months (95% CI 2.4–6.6) and 4.0 months
(95% CI 2.3–6.5), respectively (Figure 3). In the sequential
treatment arm the median PFS for these groups of patients was
5.8 months (95% CI 4.9–6.3), 6.6 months (95% CI 2.2–-4) and 4.2
months (95% CI 2.2–10.6), respectively, and for the combination
treatment arm 8.3 months (95% CI 7.6–8.7), 4.0 months (95% CI
2.3–6.5) and 8.2 months (95% CI 7.4–8.5), respectively. The
pair-wise comparison with pMMR and the two groups of dMMR
patients was not significant in the first comparison (P¼0.06), and
significant in the second comparison (P¼0.02).
Tumour response in relation to MMR status
A total of 511 patients received first-line therapy. Deficient
mismatch repair was observed in 18 patients, of whom 13 patients
showed hypermethylation of the MLH1 promoter. Of these 511
patients, dMMR was detected in 16 out of 469 patients evaluable
for response on first-line therapy, in 8 out of 288 patients evaluable
for response on second-line therapy and in none of 96 patients
evaluable for response on third-line therapy. The response and PFS
analyses are only shown for first-line due to the low number of
Table 1 Patient characteristics according to MMR status
Number of eligible
patients
Group 1 pMMR
(n¼497)
Group 2 dMMR MLH1
hypermethylation (n¼13)
Group 3 dMMR no MLH1
hypermethylation (n¼5)
P-value
#
(1 vs 2)
P-value
#
(2 vs 3)
Age
p50 years 51 (10%) 0 (0%) 2 (40%)
Median (range) 63 (31–81) 70 (54–78) 57 (35–64) 0.053 0.0051
Gender
Male 315 (63%) 7 (54%) 4 (80%) 0.49 0.29
Location of the primary tumour
Colon—left 164 (33%) — — o0.0001 —
Colon—right 122 (25%) 13 (100%) 5 (100%)
Rectosigmoid 30 (6%) — —
Rectum 161 (32%) — —
Unknown 20 (4%) — —
Histology of primary tumour
Adenocarcinoma 438 (88%) 10 (77%) 2 (40%) 0.10 0.14
Mucinous adenocarcinoma 38 (8%) 3 (23%) 3 (60%)
Adenosquamous carcinoma 4 (o1%) — —
Undifferentiated carcinoma 3 (o1%) — —
Unknown 14 (3%) — —
Differentiation grade
Well/moderate 259 (52%) 3 (23%) 2 (40%) 0.025 0.48
Poor/undifferentiated 222 (45%) 10 (77%) 3 (60%)
Unknown 16 (3%) — —
Diagnosis of metastases
o12 months before
randomization
292 (59%) 8 (62%) 1 (20%) 0.84 0.11
o 6 months before
randomization
244 (49%) 7 (54%) 1 (20%) 0.77 0.18
Number of sites involved
1 site of metastases 241 (48%) 7 (54%) 1 (20%) 0.73 0.18
41 site of metastases 250 (50%) 6 (46%) 4 (80%)
Unknown 6 (1%) — —
Primary tumour involved at
start chemotherapy
62 (12%) 3 (15%) 2 (40%) 0.37 0.54
Previous adjuvant therapy 82 (17%) 2 (15%) 2 (40%) 0.91 0.28
Resection of primary tumour 488 (98%) 13 (100%) 5 (100%) 0.49 —
#P-value logistic regression.
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(Tables 2 and 3). The overall response rate in first-line treatment
for pMMR, dMMR caused by hypermethylation of the MLH1
promoter and the total group of patients with a dMMR tumour was
31, 33 and 25%, respectively. Results on disease control in first-line
treatment in the pMMR group, the dMMR group caused by
hypermethylation of the MLH1 promoter and the total group of
patients with a dMMR tumour, were 83, 58 and 56%, respectively
(Table 3).
DISCUSSION
This is the first large randomised study in advanced CRC patients
in which the incidence of dMMR and the correlation between
sporadic dMMR and the outcome of chemotherapy is investigated.
The incidence of dMMR was low (18 out of 515 patients, 3.5%).
In 13 of these patients (2.5%) dMMR was caused by MLH1
promoter hypermethylation.
The incidence is lower as the previously reported incidence of
10–20% dMMR in sporadic CRC’s (Lothe et al, 1993; Peltomaki,
2003). We ruled out the possibility of an underestimation of dMMR
due to technical failure for several reasons. Previously it has been
shown that IHC is an accurate, highly specific and sensitive method
for detecting dMMR (Ward et al, 2001; Lindor et al, 2002; Overbeek
et al, 2008). We performed IHC staining on TMA’s (Hendriks et al,
2003), and confirmed the results on whole tissue slides and by MSI
analysis. Furthermore, MSI analysis in a random sample of patients
with pMMR as determined by IHC did confirm the results.
The low incidence in our series may be explained by a reduced
potential in stages I–III dMMR patients to develop metastases
(Lim et al, 2004; Malesci et al, 2007), as most of the previously
reported incidences were observed in these earlier stages of CRC
(Popat et al, 2005). Thus, as a consequence the incidence of dMMR
in advanced CRC studies will be lower than 10–20%. Data on the
incidence in stage IV patients are scarce and are mostly derived
from small, non-randomised studies, with a reported incidence
between 0.5 and 21% (Kochhar et al, 1997; Samowitz et al, 2001;
Liang et al, 2002; Ricciardiello et al, 2005; Malesci et al, 2007;
Muller et al, 2008). A low dMMR incidence of 0 and 2.7% was
found in advanced CRC patients with resected liver (Haddad et al,
2004) and lung metastases (Melloni et al, 2006), respectively. An
incidence of 4.4% of MLH1/MSH2 loss was reported in a large
cohort of advanced CRC patients (Braun et al, 2008).
Our results on the correlation of dMMR with clinical outcome
should be interpreted with caution due to the low number of dMMR
Table 2 OS and PFS according to MMR status with the number of events in italic
Number of
patients
PMMR
(n¼497)
dMMR MLH1
hypermethylation
(n¼13)
dMMR total
(n¼18)
P-value
#
pMMR vs dMMR
hypermethylation
P-value
#
pMMR vs dMMR
total
Overall survival (months)
Median (95% CI) 17.9 (16.2–18.9) 7.4 (3.7–16.9) 10.2 (5.9–19.8) 0.27 0.41
n¼440 n¼11 n¼15
Sequential treatment
Median (95% CI)
17.2 (14.7–18.8) 12.4 (3.2– –4) 12.7 (7.4–22.2) 0.58 0.47
n¼230 n¼4n ¼7
Combination treatment
Median (95% CI)
18.3 (16.2–20.6) 6.2 (3.6–31.3) 6.2 (3.6–31.3) 0.25 0.58
n¼210 n¼7n ¼8
PFS (months)
Median (95% CI) 6.9 (6.3–7.7) 4.3 (2.4–6.6) 4.0 (2.3–6.5) 0.85 0.28
n¼490 n¼12 n¼17
Sequential treatment
Median (95% CI)
5.8 (4.9–6.3) 6.6 (2.2–-4 ) 4.2 (2.2–10.6) 0.27 0.72
n¼247 n¼4n ¼7
Combination treatment
Median (95% CI)
8.3 (7.6–8.7) 4.0 (2.3–6.5) 4.0 (2.3–6.5) 0.06 0.02
n¼243 n¼8n ¼10
#P-value Cox regression.
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Months from randomisation 
0.0
0.2
0.4
0.6
0.8
1.0
O
v
e
r
a
l
l
 
s
u
r
v
i
v
a
l
 
p
r
o
b
a
b
i
l
i
t
y
 
  pMMR
dMMR
Figure 2 OS by MMR status.
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Figure 3 PFS by MMR status.
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spatients. We found a non-significant decrease in median OS of 17.9
vs 10.2 months, and in median PFS of 6.9 vs 4.0 months in pMMR
vs dMMR patients treated with chemotherapy, with a decreased
disease control rate of 83 vs 56%, respectively. These results are
difficult to compare with previously reported results for several
reasons. First, dMMR has been tested as a predictive marker in
advanced CRC in only one randomised study (Muller et al, 2008). In
this study with 474 patients, tumour tissue was available from 104
patients of whom only 4 patients treated with 5FU and oxaliplatin
tested positive for dMMR. Second, we used capecitabine as a
fluoropyrimidine. It is yet unknown whether the outcome of 5FU and
capecitabine differs in respect to the MMR status of patients. Third, in
contrast to most studies we differentiated between dMMR caused by
hypermethylation of the MLH1 promoter, dMMR without MLH1
promoter hypermethylation, and pMMR. Hereditary and sporadic
dMMR tumours may differ in terms of pathologic features, under-
lying molecular alterations, and prognosis, and it is known that
patients with dMMR tumours with overlapping hypermethylator
phenotype have a worse clinical outcome compared to dMMR
tumours without promoter hypermethylation (Hawkins et al, 2002;
Ward et al, 2003; McGivern et al,2 0 0 4 ;B e n a t t iet al,2 0 0 5 ;J o h n s o n
et al,2 0 0 5 ;J a s s ,2 0 0 7 ) .
A reduced chemosensitivity was observed in CRC cell lines with
MLH1 promoter hypermethylation treated with fluoropyrimidines
(Arnold et al, 2003). Although we found a decreased disease
control rate in dMMR patients, our numbers are too small to draw
meaningful conclusions. Definite proof for a reduced chemosensi-
tivity of advanced dMMR tumours can only be obtained from
prospective randomised studies with chemotherapy vs observa-
tion. However studies with this design are considered unethical
given the benefit of chemotherapy. We considered a control group
within the same prospective trial which therefore was selected,
treated and monitored in exactly the same way as the most
appropriate alternative.
In conclusion, dMMR caused by hypermethylation of the MLH1
–promoter is a rare event in advanced CRC patients. This supports
the hypothesis that dMMR tumours have a reduced metastatic
potential. Given the low incidence of dMMR in advanced CRC
patients, our results do not allow any meaningful conclusions on
the correlation between dMMR status and clinical outcome. This
topic should be addressed by a pooled analysis of multiple trials.
The low incidence of dMMR does not justify the need for standard
dMMR testing in advanced CRC patients.
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